Hope S. Rugo, MD, Talks Aromatase Inhibitors Plus Ribociclib in HR+/HER2– Advanced Breast Cancer
July 25th 2022Hope S. Rugo, MD, FASCO, gave an overview of ribociclib plus aromatase inhibitor use vs abemaciclib plus aromatase inhibitors for patients with hormone receptor-positive, HER2-negative advanced breast cancer.
Hope S. Rugo, MD, on Comparing CDK4/6 Inhibitors in HR+/HER2– Advanced Breast Cancer
July 24th 2022Hope S. Rugo, MD, FASCO, reviewed data from a matching-adjusted indirect comparison study which analyzed quality of life in patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with ribociclib- or abemaciclib-based regimens.
Mark Pegram, MD, Talks Predictors of Optimal Adjuvant ET Duration in Early-Stage HR+ Breast Cancer
June 30th 2022Mark Pegram, MD, spoke about predictive and prognostic factors used to determine which patients with early-stage hormone receptor–positive breast cancer benefit from extended vs standard adjuvant endocrine therapy.
Mark Pegram, MD, Reviews Utility of Breast Cancer Index in Early-Stage HR+ Breast Cancer
June 28th 2022Mark Pegram, MD, spoke about using the Breast Cancer Index and Clinical Treatment Score post-5 years to determine outcomes for patients with early-stage hormone receptor–positive breast cancer treated with adjuvant endocrine therapy.
Patritumab Deruxtecan Yields Positive Response Rates in HER3-Expressing Metastatic Breast Cancer
June 5th 2022Patritumab deruxtecan induced positive efficacy, according to the phase 1/2 U31402-J101 trial in patients with HER3-expressing metastatic breast cancer or metastatic triple-negative breast cancer.
Trastuzumab Deruxtecan Use for Metastatic HER2+ Breast Cancer Validated at Safety Analysis
June 4th 2022An acceptable safety reported at a follow-up analysis of the phase 3 DESTINY-Breast03 study has reinforced use of fam-trastuzumab deruxtecan-nxki for patients with HER2-positive unresectable or metastatic breast cancer
Despite Increased Use of Telemedicine for Cancer Care During COVID-19, Disparities Persist
May 26th 2022The findings of this retrospective study of more than 25,000 patients with cancer newly diagnosed during the COVID-19 pandemic highlight a need to reduce the inequities in telemedicine use for cancer care, according to the study’s lead author.